MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-09-2026
Becton, Dickinson and Company Accounts Receivables 2011-2026 | BDX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.99 B | 3.03 B | 2.53 B | 2.19 B | 2.35 B | 2.4 B | 2.34 B | 2.32 B | 1.74 B | 1.62 B | 1.62 B | 1.19 B | 1.24 B | 1.25 B | 1.23 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 B | 1.19 B | 2 B |
Quarterly Accounts Receivables Becton, Dickinson and Company
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.51 B | 2.94 B | 3.03 B | 2.64 B | 2.6 B | 2.56 B | 2.27 B | 2.41 B | 2.41 B | 2.28 B | 2.19 B | - | 2.3 B | 2.18 B | 2.5 B | 2.08 B | 2.5 B | 2.37 B | 2.4 B | 2.4 B | 2.4 B | 2.07 B | 2.34 B | 2.34 B | 2.34 B | 2.22 B | 2.32 B | 2.32 B | 2.32 B | 2 B | 1.74 B | 1.74 B | 1.74 B | 1.52 B | 1.62 B | 1.62 B | 1.57 B | 1.51 B | 1.62 B | 1.64 B | 1.62 B | 1.03 B | 1.19 B | 1.19 B | 1.19 B | 1.11 B | 1.24 B | 1.24 B | 1.24 B | 1.17 B | 1.25 B | 1.25 B | 1.25 B | 1.14 B | 1.23 B | 1.23 B | 1.23 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 B | 1.03 B | 1.9 B |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
66.7 M | $ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 10.6 | -1.03 % | $ 433 M | USA |
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
16.1 M | $ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
ICU Medical
ICUI
|
181 M | $ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 472.16 | -1.48 % | $ 169 B | USA |
 |
The Cooper Companies
COO
|
829 M | $ 69.92 | -2.24 % | $ 13.9 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
717 K | $ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
116 K | - | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
746 K | - | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
1.7 B | $ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 18.36 | 1.16 % | $ 846 M | USA |
 |
Nephros
NEPH
|
1.5 M | $ 3.5 | -7.89 % | $ 36.4 M | USA |
 |
ResMed
RMD
|
576 M | $ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
7.79 M | $ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
50.1 M | $ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
3.39 M | $ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
574 M | $ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 21.57 | 1.27 % | $ 1.45 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 214.57 | 1.05 % | $ 21.2 B | USA |
 |
Milestone Scientific
MLSS
|
475 K | $ 0.28 | -3.75 % | $ 22.3 M | USA |